DEALS: Merck KGaA buys Serono for $13.3B


Merck KGaA buys Serono for $13.3B


DEALS

WHO

WITH

WHAT

SCOOP

Merck KGaA

Serono

$13.3B buyout

The deal appears to have been heavily influenced by Merck's decision to keep Serono's headquarters in Geneva.

Altana

Nycomed

$5.8B sale

Germany-based Altana is selling its pharmaceutical business to Denmark's Nycomed for €4.5 billion.

Hospira

Mayne Pharma

$2.63B buyout

Hospira sees the move as a big boost to its international efforts in marketing generic injectables.

Millennium Pharmaceuticals

AnorMed

$515M buyout

Millennium Pharmaceuticals has beat out out Genzyme's bid for Millennium Pharmaceuticals.

UCB

Schwarz Pharma

$5.6M buyout

The two companies will enjoy about €3.3 billion in revenue and an R&D budget of €770 million.

Novartis

Cell Therapeutics

$285M licensing deal

The deal is for the cancer therapy Xyotax.

Elan

Transition Therapeutics

$200M licensing deal

The pact covers AZD-103, which is in Phase II.

Pfizer

TransTech

$155M licensing deal

The deal covers the worldwide rights to compounds that target the receptor for advanced glycation end products (RAGE) and have potential use in the treatment of Alzheimer's disease.

Pfizer

Atugen/SR Pharma

$95M licensing deal

The deal is for an RNAi treatment for age-related macular degeneration developed with Quark Biotech.

Biogen Idec

MondoBiotech

$37.5M licensing deal

Biogen Idec is gaining the rights to develop a new therapy for pulmonary arterial hyperntension.

Schering

AstraZeneca

Development pact

Germany's Schering and the UK's AstraZeneca are joining forces to develop a new therapy for breast cancer.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.